PharmaEngine, Inc. (TPEX:4162)

Taiwan · Delayed Price · Currency is TWD

57.30

+0.60 (1.06%)

Jun 18, 2026, 1:30 PM CST

-29.95% (1Y)

Market Cap	8.23B -38.0%
Revenue (ttm)	963.83M -62.1%
Net Income	422.55M -76.1%
EPS	2.93 -76.1%
Shares Out	143.68M
PE Ratio	19.56
Forward PE	n/a
Dividend	2.00 (3.49%)
Ex-Dividend Date	Aug 13, 2025

Volume	382,593
Open	57.10
Previous Close	56.70
Day's Range	56.90 - 57.80
52-Week Range	53.00 - 82.20
Beta	0.16
Analysts	Hold
Price Target	120.00 (+109.42%)
Earnings Date	Aug 11, 2026

About PharmaEngine

PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is also developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematological tumors and solid tumors. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan. [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2002

Employees 45

Stock Exchange Taipei Exchange

Ticker Symbol 4162

Full Company Profile

Financial Performance

In 2025, PharmaEngine's revenue was 911.42 million, a decrease of -63.88% compared to the previous year's 2.52 billion. Earnings were 387.64 million, a decrease of -77.86%.

Financial Statements